振东制药：治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊NDA已获CDE受理

证券之星20:52

证券之星消息，振东制药(300158)07月29日在投资者关系平台上答复投资者关心的问题。

投资者提问：公司在研的创新药有哪些？主要用于治疗哪些病症？目前处于什么阶段？

振东制药回复：尊敬的投资者您好！目前公司引进的创新药为治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊，该产品上市许可申请（NDA）已于2025年12月获国家药监局药品审评中心（CDE）正式受理，目前正处于正常审批流程中。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2655152870?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-30 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655152870","market":"sh","top_or_hot":-1,"title":"振东制药：治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊NDA已获CDE受理","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300158\">振东制药</a>(300158)07月29日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：公司在研的创新药有哪些？主要用于治疗哪些病症？目前处于什么阶段？</p><p>振东制药回复：尊敬的投资者您好！目前公司引进的创新药为治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊，该产品上市许可申请（NDA）已于2025年12月获国家药监局药品审评中心（CDE）正式受理，目前正处于正常审批流程中。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>振东制药：治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊NDA已获CDE受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n振东制药：治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊NDA已获CDE受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-30 20:52 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026073000037388.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，振东制药(300158)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在研的创新药有哪些？主要用于治疗哪些病症？目前处于什么阶段？振东制药回复：尊敬的投资者您好！目前公司引进的创新药为治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊，该产品上市许可申请（NDA）已于2025年12月获国家药监局药品审评中心（CDE）正式受理，目前正处于正常审批流程中。药品研发周期长，药品...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026073000037388.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://stock.stockstar.com/RB2026073000037388.shtml","article_id":"2655152870","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655152870","pubTimestamp":1785415924,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，振东制药(300158)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在研的创新药有哪些？主要用于治疗哪些病症？目前处于什么阶段？振东制药回复：尊敬的投资者您好！目前公司引进的创新药为治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊，该产品上市许可申请（NDA）已于2025年12月获国家药监局药品审评中心（CDE）正式受理，目前正处于正常审批流程中。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300158":"振东制药","BK0239":"医药制造","BK0060":"抗癌","BK0186":"小盘成长"},"translate_title":"Zhendong Pharmaceutical: The NDA of Lactobacillus grazieri double live bacteria capsules for the treatment of bacterial vaginitis has been accepted by CDE","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300158":1.5},"content_text":"证券之星消息，振东制药(300158)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在研的创新药有哪些？主要用于治疗哪些病症？目前处于什么阶段？振东制药回复：尊敬的投资者您好！目前公司引进的创新药为治疗细菌性阴道炎的格氏乳杆菌二联活菌胶囊，该产品上市许可申请（NDA）已于2025年12月获国家药监局药品审评中心（CDE）正式受理，目前正处于正常审批流程中。药品研发周期长，药品上市存在不确定性，后续有涉及披露事项公司会及时公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655152870","isCrawlerRequest":true}